Dual Inhibitors for Alzheimer's Disease Treatment
Summary
USPTO published patent application US20260092039A1 for dual inhibitors (soluble epoxide hydrolase and glutaminyl cyclase inhibitors) useful for Alzheimer's disease treatment. Inventors from Spain and Germany filed Application No. 19161626 on March 4, 2024, with the application published April 2, 2026. The compounds also reduce pro-inflammatory cytokines, exhibit low cytotoxicity, and have good blood-brain barrier permeability.
What changed
USPTO published patent application US20260092039A1 claiming chemical compounds (I) that simultaneously inhibit soluble epoxide hydrolase (sEH) and glutaminyl cyclase (QC) for preventing or treating Alzheimer's disease. The application (No. 19161626) was filed March 4, 2024 and formally published April 2, 2026. Named inventors include researchers from Spain and Germany. The claimed compounds also reduce pro-inflammatory cytokine levels in LPS-stimulated BV2 cells and demonstrate low cytotoxicity with good BBB permeability.\n\nPharmaceutical companies and drug manufacturers developing neurological or Alzheimer's disease treatments should review this patent publication for prior art and freedom-to-operate analysis. The patent, if granted, would provide 20-year protection from the March 2024 filing date. Research institutions and biotech firms working on sEH or QC inhibitors should assess potential overlap with their own compound pipelines.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
Application US20260092039A1 Kind: A1 Apr 02, 2026
Inventors
Diego MUÑOZ-TORRERO LÓPEZ-IBARRA, Santiago VÁZQUEZ CRUZ, Noemí MARTÍNEZ CONDE, Eugènia-Alexandra PUJOL BECH, Tina LÖFFLER, Daniela BRUNNER, Manuela PROKESCH, Roland RABL, Birgit HUTTER-PAIER
Abstract
Compounds (I) are provided, where R1 and R2 are H or (C1-C3)-alkyl; X is a linear methylene chain of formula —[CH2]n— with n=0, 1 or 2, or a biradical from a branched saturated (C2-C4)-alkylene chain; and A is either a C-radical from a non-aromatic polycyclic 6- to 15-membered carbocyclic ring system, or a C-radical from a polycyclic 6- to 15-membered heterocyclic ring system having one or two O, S or N; wherein the C-radicals are unsubstituted or substituted. Compounds (I) are simultaneously inhibitors of soluble epoxide hydrolase and inhibitors of glutaminyl cyclase. Besides, they reduce the levels of pro-inflammatory cytokines in LPS stimulated BV2 cells, display low cytotoxicity, and have good BBB permeability. Thus, they are useful as multitarget compounds for the prevention or treatment of Alzheimer's disease.
CPC Classifications
C07D 233/61 A61K 31/417 A61K 31/4178 C07D 493/18
Filing Date
2024-03-04
Application No.
19161626
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.